Resolution Therapeutics

Founded: 2020
CEO: Amir Hefni
Founders: Prof. Stuart Forbes
Prof. John Campbell
Shareholding: 83%
Stage: Pre-clinical
Number of employees: 20+
Raised in Series B financing in October 2024: £63.5m

Unless stated all financials at 31 December 2024

Resolution website

Resolution is developing macrophage cell therapies to repair inflammatory organ damage.

Syncona co-founded Resolution following a two year collaboration with researchers at the University of Edinburgh and the Scottish National Blood Transfusion Service.

Resolution is developing macrophage cell therapies to repair inflammatory organ damage, including treatment of end-stage chronic liver disease. Macrophages are cells of the innate immune system which orchestrate the body’s defence against infection and injury; the company is built upon more than a decade of work in the Founders’ laboratories characterising the role of macrophages in organ repair, including the liver, both in the pre-clinical and clinical settings.

Investment thesis

An opportunity to create the leading inflammation-focused macrophage cell therapy business, focusing initially on treatment of liver cirrhosis. The goal is to repair the livers of patients sufficiently to reduce the risk of decompensation. Future opportunity lies in lung and kidney repair in chronic fibrotic disease.

Unmet medical need

Chronic inflammatory organ damage represents a major burden to patients. If left untreated, liver cirrhosis will often progress to decompensation through significant loss of liver function. Today there are no efficacious treatments to prevent deterioration in the latter stages of the disease, thus leaving costly and burdensome liver transplantation often as the only option.

Market opportunity

1-2 million people estimated to be affected by liver cirrhosis across major Western markets¹
The global liver transplantation market in 2023 was $1.5 billion in 2023²

¹Scaglione et al., Journal of Clinical Gastroenterology, 2015

²Liver Transplantation Market, Persistence Market Research

Syncona team

Roel Bulthuis

Roel Bulthuis is Managing Partner, Head of Investments of Syncona Investment Management Limited Roel is currently a Managing Partner at Syncona, where he manages the investment team and utilises more than 20 years of life science venture capital, business development and investment banking experience to help Syncona deliver value through the investment cycle. He is a Board member of iOnctura and A…

View Roel's biography

Position

Board observer

Qualification

MSc, MBA

Edward Hodgkin

Edward Hodgkin is a Managing Partner of Syncona Investment Management Ltd. He is currently the Chair of Mosaic Therapeutics and Slingshot Therapeutics, and a Board member of Resolution Therapeutics and OMass Therapeutics. He was also previously the first CEO and a board member of Autolus Therapeutics (NASDAQ:AUTL), and the former CEO of Resolution Therapeutics. Within the Syncona life science team…

View Edward's biography

Position

Board member

Qualification

PhD

Gonzalo Garcia

Gonzalo is a Principal of Syncona Investment Management Limited. Gonzalo is a Director on the Board of Yellowstone Biosciences and Resolution Therapeutics. He was closely involved in the foundation of both companies, including their strategic and operational set-up, through hands-on membership of their founding leadership teams. Previously, Gonzalo was a Project Leader at Boston Consulting Group w…

View Gonzalo's biography

Position

Board member

Qualification

PhD

Gwenaelle Pemberton

Gwenaelle is a Regulatory Advisor to Syncona Investment Management Ltd. Gwenaelle is a senior regulatory leader with over 30 years’ experience in global regulatory strategy in biopharma. Most recently, Gwenaelle was Vice President International Regulatory Affairs at Gilead, leading the International Regulatory Group which was responsible for regulatory activities worldwide, excluding the US. Gwena…

View Gwenaelle's biography